Outcome of unrelated donor stem cell transplantation for children with severe aplastic anemia
- PMID: 18307564
- PMCID: PMC3164958
- DOI: 10.1111/j.1365-2141.2008.07030.x
Outcome of unrelated donor stem cell transplantation for children with severe aplastic anemia
Abstract
For children with severe aplastic anemia (SAA) who fail immunosuppressive therapy and lack a human leucocyte antigen (HLA)-matched sibling donor, unrelated donors provide a source of hematopoietic stem cells. Data from 195 children with acquired SAA who underwent unrelated donor transplantation between 1989 and 2003 were analyzed. Neutrophil recovery (86% at day-28) was higher with total body irradiation-containing conditioning regimen and in younger recipients (aged < or =16 years) receiving grafts from older donors (aged >40 years). Recovery was lower after mismatched transplants and transplantations prior to 1997. Mortality rates were higher after mismatched transplants, in recipients with a poor performance score, and when the interval between diagnosis and transplantation was longer than 4 years. When restricted to donor-recipient pairs with allele-level HLA typing (8-loci; n = 118), mortality rates were also higher after mismatched transplants and older recipients receiving grafts from older donors; 5-year probabilities of overall survival after HLA-A, -B, -C, -DRB1 matched and mismatched transplants adjusted for donor and recipient age were 57% and 39%, respectively (P = 0.008). The data suggest that unrelated donor transplantation is an acceptable alternative for children; early referral for transplantation and identification of an HLA-matched (allele-level) donor offers the best outcome.
Figures
Similar articles
-
Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient.Haematologica. 2007 May;92(5):589-96. doi: 10.3324/haematol.10899. Haematologica. 2007. PMID: 17488681
-
Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia.Bone Marrow Transplant. 2006 Apr;37(7):641-9. doi: 10.1038/sj.bmt.1705299. Bone Marrow Transplant. 2006. PMID: 16489361
-
Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.Biol Blood Marrow Transplant. 2017 Sep;23(9):1498-1508. doi: 10.1016/j.bbmt.2017.05.026. Epub 2017 May 26. Biol Blood Marrow Transplant. 2017. PMID: 28554856
-
Bone marrow transplantation for acquired severe aplastic anemia.Hematol Oncol Clin North Am. 2014 Dec;28(6):1145-55. doi: 10.1016/j.hoc.2014.08.004. Epub 2014 Oct 5. Hematol Oncol Clin North Am. 2014. PMID: 25459184 Review.
-
Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia.Semin Hematol. 2000 Jan;37(1):43-55. doi: 10.1016/s0037-1963(00)90029-5. Semin Hematol. 2000. PMID: 10676910 Review.
Cited by
-
Second allogeneic hematopoietic stem cell transplantation in children with severe aplastic anemia.Bone Marrow Transplant. 2015 Oct;50(10):1312-5. doi: 10.1038/bmt.2015.153. Epub 2015 Jun 29. Bone Marrow Transplant. 2015. PMID: 26121106
-
Alternative donor transplant of benign primary hematologic disorders.Bone Marrow Transplant. 2015 May;50(5):619-27. doi: 10.1038/bmt.2015.1. Epub 2015 Feb 9. Bone Marrow Transplant. 2015. PMID: 25665040 Free PMC article. Review.
-
Fludarabine-Cyclophosphamide-Based Conditioning with Antithymocyte Globulin Serotherapy Is Associated with Durable Engraftment and Manageable Infections in Children with Severe Aplastic Anemia.J Clin Med. 2021 Sep 26;10(19):4416. doi: 10.3390/jcm10194416. J Clin Med. 2021. PMID: 34640434 Free PMC article.
-
Unrelated donor stem cell transplantation in acquired severe aplastic anemia: a systematic review.Haematologica. 2009 Dec;94(12):1732-42. doi: 10.3324/haematol.2009.007583. Epub 2009 Jul 31. Haematologica. 2009. PMID: 19648165 Free PMC article.
-
The state of the art in the treatment of severe aplastic anemia: immunotherapy and hematopoietic cell transplantation in children and adults.Front Immunol. 2024 Apr 5;15:1378432. doi: 10.3389/fimmu.2024.1378432. eCollection 2024. Front Immunol. 2024. PMID: 38646536 Free PMC article. Review.
References
-
- Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F, Gabbas A, Dufour C, Arcese W, Testi G, Broccia G, Carotenuto M, Coser P, Barbui T, Leoni P, Ferster A. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood. 2000;95:1931–1934. - PubMed
-
- Bunin N, Leahey A, Kamani N, August C. Bone marrow transplantation in pediatric patients with severe aplastic anemia: cyclophosphamide and anti-thymocyte globulin conditioning followed by recombinant human granulocyte-macrophage colony stimulating factor. J Pediatr Hematol Oncol. 1996;18:68–71. - PubMed
-
- Camitta BM, Doney K. Immunosuppressive therapy for aplastic anemia: indications, agents, mechanisms, and results. Am J Pediatr Hematol Oncol. 1990;12:411–424. - PubMed
-
- Camitta BM, Thomas ED, Nathan DG, Gale RP, Kopecky KJ, Rappeport JM, Santos G, Gordon-Smith EC, Storb R. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood. 1979;53:504–514. - PubMed
-
- Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials